Ginkgo Bioworks (DNA) Projected to Post Earnings on Thursday

Ginkgo Bioworks (NYSE:DNA - Get Free Report) is expected to post its Q2 2025 quarterly earnings results after the market closes on Thursday, August 7th. Analysts expect Ginkgo Bioworks to post earnings of ($1.44) per share and revenue of $41.60 million for the quarter. Ginkgo Bioworks has set its FY 2025 guidance at EPS.Ginkgo Bioworks (NYSE:DNA - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The company reported ($1.58) EPS for the quarter, missing the consensus estimate of ($1.23) by ($0.35). Ginkgo Bioworks had a negative return on equity of 52.35% and a negative net margin of 198.84%. The company had revenue of $48.32 million during the quarter, compared to analysts' expectations of $38.70 million. On average, analysts expect Ginkgo Bioworks to post $-10 EPS for the current fiscal year and $-6 EPS for the next fiscal year. Get Ginkgo Bioworks alerts:Ginkgo Bioworks Stock PerformanceDNA stock opened at $12.18 on Friday. The firm has a 50 day moving average price of $10.05 and a 200-day moving average price of $9.35. Ginkgo Bioworks has a 52-week low of $5.00 and a 52-week high of $16.85. The firm has a market capitalization of $712.90 million, a price-to-earnings ratio of -1.33 and a beta of 1.50. Institutional Investors Weigh In On Ginkgo BioworksA number of hedge funds have recently modified their holdings of the business. Acadian Asset Management LLC bought a new position in Ginkgo Bioworks in the 1st quarter worth $120,000. Goldman Sachs Group Inc. lifted its stake in Ginkgo Bioworks by 25.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 686,767 shares of the company's stock worth $3,915,000 after purchasing an additional 139,126 shares in the last quarter. Millennium Management LLC lifted its stake in Ginkgo Bioworks by 113.1% in the 1st quarter. Millennium Management LLC now owns 1,427,600 shares of the company's stock worth $8,137,000 after purchasing an additional 757,535 shares in the last quarter. Finally, AQR Capital Management LLC lifted its stake in Ginkgo Bioworks by 322.6% in the 1st quarter. AQR Capital Management LLC now owns 158,939 shares of the company's stock worth $906,000 after purchasing an additional 121,326 shares in the last quarter. Institutional investors own 78.63% of the company's stock. Ginkgo Bioworks Company Profile (Get Free Report)Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming in the United States. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. It serves pharma and biotech, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries.See AlsoFive stocks we like better than Ginkgo BioworksHow to Effectively Use the MarketBeat Ratings ScreenerIs PG&E an AI Power Play? Why Options Traders Are Betting BigWhat is a Dividend Harvesting Strategy and How Can Investors Profit from it?MarketBeat Week in Review – 07/28 - 08/01How to Choose Top Rated StocksWill Hims & Hers Fall Along With Novo Nordisk?This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in Ginkgo Bioworks Right Now?Before you consider Ginkgo Bioworks, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Ginkgo Bioworks wasn't on the list.While Ginkgo Bioworks currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here